Physician profile
John S Dryden
NPI 1821076035
$2,462.53
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $730 · 2020: $497 · 2021: $191 · 2022: $1,045.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Penumbra, INC. | $1,028.34 | 2022 | |
| Astellas Pharma US INC | $400.05 | 2019-2022 | |
| Isoray, INC | $244.13 | 2020 | |
| Boston Scientific Corporation | $188.49 | 2019-2021 | |
| Janssen Biotech, INC. | $132.70 | 2019-2020 | |
| Abbvie INC. | $94.49 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $57.50 | 2019-2021 | |
| Coloplast Corp | $55.03 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.41 | 2019 | |
| Neotract INC. | $38.70 | 2020 | |
| Ferring Pharmaceuticals INC. | $34.63 | 2019-2020 | |
| Genzyme Corporation | $34.51 | 2019 | |
| Teleflex LLC | $31.04 | 2021 | |
| Merck Sharp & Dohme LLC | $21.59 | 2021 | |
| Cook Medical LLC | $19.40 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $16.24 | 2019 | |
| Dendreon Pharmaceuticals LLC | $13.28 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dryden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.